John Doux, MD

John Doux has been an analyst at Palo Alto Investors since 2004. He currently serves as a board director of Lutris Pharma, and served previously as board chair of ValenzaBio (acquired by ACELYRIN), and as a board director of Ceptaris Therapeutics (acquired by Actelion Pharmaceuticals) and Palvella Therapeutics. A board certified dermatologist, Dr. Doux is a fellow of the American Academy of Dermatology and a co-founder and prior board member of the Dermatology Summit and Dermatology Innovation Forum. He earned his B.S. and M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow in the laboratory of Dr. David Woodley. He completed his training at Brigham and Women’s Hospital and Stanford Medical Center and earned an M.B.A. at the Wharton School of Business, where he was a Palmer Scholar.